[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperinsulinism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperinsulinism":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,74,108,137,164,185,215],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100515272","phase-1-study-to-evaluate-biomarkers-and-safety-of-dapagliflozin-concomitant-with-neoadjuvant-therapy-100515272",false,"NCT05989347","Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy","A Pilot Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy for Patient With HER2-negative Early-stage Breast Cancer and Hyperinsulinemia","Inclusion Criteria:\n\n* Women \\> 18 years of age with newly diagnosed, histologically confirmed, clinical stage I-III, HER2-negative - either ER+ or triple negative - invasive breast cancer as defined by ASCO CAP guidelines for whom neoadjuvant chemotherapy would be indicated. The following chemotherapy regimens are acceptable:\n\n  1. Weekly or dose dense paclitaxel, followed by dose dense doxorubicin plus cyclophosphamide\n  2. Docetaxel plus cyclophosphamide\n  3. Docetaxel plus carboplatin plus or minus pembrolizumab\n  4. Paclitaxel plus carboplatin concurrent with every 3 week pembrolizumab followed by dose dense doxorubicin plus cyclophosphamide concurrent with every 3 week pembrolizumab (KEYNOTE-522 regimen; only for participants with triple negative breast cancer)\n* BMI ≥ 25 kg\u002Fm2\n* Hyperinsulinemia defined as HOMA-IR ≥ 2.5.\n* Willing and able to provide written informed consent for the trial.\n* Has at least one (1) physical 4-5-micron single H\\&E slide from diagnostic biopsy available\n* Female participants of childbearing potential should have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Female participants must be 1 year post-menopausal orsurgically sterile, Women of childbearing potential who are sexually active with a non-sterilized male partner must agree to follow their chemotherapy provider's instructions for birth control.\n* Participants should have adequate organ function to tolerate chemotherapy, as defined by:\n\n  1. peripheral granulocyte count of \\> 1,500\u002Fmm3\n  2. platelet count \\> 100,000\u002Fmm3\n  3. hemoglobin \\>9 g\u002FdL\n  4. total bilirubin \\\u003C 1.5 x upper limit of normal (ULN)\n  5. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) each \\\u003C 1.5 x ULN\n  6. serum creatinine \\\u003C 1.5 x ULN\n  7. INR\u002FPT\u002FPTT each \\\u003C 1.5 x ULN\n* Able to swallow oral formulation of the study agent\n* Subjects should not donate blood while participating in this study, or for at least 90 days following the last dose of chemotherapy\n\nExclusion Criteria:\n\n* Participants who underwent partial excisional biopsy or lumpectomy, segmental mastectomy or modified radical mastectomy or sentinel node biopsy and therefore cannot be assessed accurately for pathologic response, are not eligible.\n* Participants currently pregnant or breastfeeding.\n* Participants for whom any of the planned chemotherapies are contraindicated.\n* Participants with currently diagnosed type I or II diabetes mellitus.\n* Participants taking any antidiabetic medication that would affect insulin resistance or hyperinsulinemia (i.e. TZD, GLP-1RA, DPP-4i, SGLT2i, metformin) in the past one month.\n* Participants with history of hypersensitivity reaction to dapagliflozin.\n* Participants with eGFR \\\u003C 25.\n* History of recurrent (three or more occurrences within 12 months, or two or more occurrences within 6 months) urinary tract infections.\n* Currently participating in weight loss programs or weight change in the past 3 months (\\> 5% current body weight) or have a history of gastrointestinal surgery.\n* Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, intranasal influenza, rabies, BCG, and typhoid vaccine.\n* Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.","FEMALE","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.",[26,27,28],"Breast Cancer","Hyperinsulinism","HER2-negative Breast Cancer","RECRUITING","2026-05-20",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2024-10-15",{"date":37,"type":20},"2027-12",{"name":39,"class":40},"Yale University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":41},"100512271","determinants-of-insulin-sensitivity-by-age-sex-raceethnicity-bmi-and-pcos-diagnosis-100512271","NCT05950282","Determinants of Insulin Sensitivity by Age, Sex, Race\u002FEthnicity, BMI, and PCOS Diagnosis","Measuring Fasting Insulin and HOMA-IR by Age, Sex, Race\u002FEthnicity, BMI, and PCOS Diagnosis","DAISY","Inclusion Criteria Age: Participants aged 18+ years Sex: Both males and females Race\u002FEthnicity: Participants from diverse racial and ethnic backgrounds BMI: Participants across a range of body mass index (BMI) values PCOS Diagnosis: Participants with and without a confirmed diagnosis of PCOS based on established diagnostic criteria\n\nParticipants must have completed metabolic testing within one month prior to enrollment, including:\n\n* Fasting insulin\n* Hemoglobin A1c (A1c)\n* Complete lipid panel\n* Triglycerides Laboratory testing must be completed through a healthcare provider, an independent laboratory, or by using an Insara Insulin Testing Kit Laboratory values must be obtained following a minimum 8-hour fast Participants must have complete laboratory data for all required measures\n\nExclusion Criteria Age: Participants below 18 years Sex: None. Both males and females are included Race\u002FEthnicity: None. Participants from all racial and ethnic backgrounds are included Endocrine Disorders: Participants with other endocrine disorders affecting insulin levels (e.g., insulin-secreting tumors) Significant recent weight change: Loss of more than 5% of body weight within the previous month Pregnancy or breastfeeding Acute illness or infection within the past 2 weeks Use of medications known to significantly affect insulin or glucose metabolism will be recorded and accounted for in analysis",true,"ALL",{"count":53,"type":20},150,"1 Year","OBSERVATIONAL","The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race\u002Fethnicity, BMI, and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.",[58,59,27,60,61],"Insulin Resistance","Polycystic Ovary Syndrome","Obesity","Metabolic Syndrome",[63,64,58,61,60,65],"PCOS","Hyperinsulinemia","Type 2 Diabetes","2026-04-27",{"date":68,"type":33},"2026-05-01",{"date":70,"type":33},"2024-02-01",{"date":37,"type":20},{"name":73,"class":40},"Ali Chappell",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":50,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":95,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100480983","cognitive-behavioral-therapy-and-exercise-training-in-adolescents-at-risk-for-type-2-diabetes-100480983","NCT05543083","Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes","CBTeX","Inclusion Criteria:\n\n* Female\n* Age 12-17 years\n* Body Mass Index (BMI)\\>= 85 for age and sex\n* Type 2 Diabetes (T2D) first-or second-degree relative\n* Center for Epidemiologic Studies Depression Scale (CES-D) total score \\>=21\n\nExclusion Criteria:\n\n* T2D\u002F Type 1 Diabetes (T1D) or any major medical condition (e.g. cardiovascular, renal) that would prohibit the ability to participate in exercise training\n* Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) conduct disorder, substance abuse\u002F dependence, obsessive compulsive disorder, panic attacks, post-traumatic stress disorder, anorexia\u002Fbulimia, \\& schizophrenia\n* Insulin sensitizers, weight loss medications \\& chronic steroids\n* Structured weight loss treatment or bariatric surgery\n* Pregnancy, nursing","12 Years","17 Years",{"count":84,"type":20},300,[86],"NA","The investigators are doing this study to learn more about how to prevent type 2 diabetes in teenage girls. The purpose of this study is to find out if taking part in a cognitive-behavioral therapy group, exercise training group, or a combination of cognitive-behavioral therapy and exercise training groups, decreases stress, improves mood, increases physical activity and physical fitness, and decreases insulin resistance among teenagers at risk for diabetes.",[58,89,90,91,92,27,93,94],"Depression","Depressive Disorder","Mood Disorders","Mental Disorder in Adolescence","Glucose Metabolism Disorders","Metabolic Disease",[96,97],"Adolescent Type 2 Diabetes Prevention","Exercise Training","2026-04-17",{"date":100,"type":33},"2026-04-22",{"date":102,"type":33},"2023-06-02",{"date":104,"type":20},"2029-03-31",{"name":106,"class":40},"Colorado State University",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":50,"sex":51,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":41},"100552825","understanding-beta-cell-disorders-through-the-study-of-rare-genotypes-endure-100552825","NCT06478121","Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE)","ENDURE","Inclusion Criteria\n\n* Mental capacity to give informed consent\n* Of any sex, ethnicity, location.\n* Group 1: Cases will have a genetic variant(s) resulting in a beta cell disorder.\n* Group 2: Controls will not have a genetic variant(s) resulting in a beta cell disorder and will be matched to a Case for sex, age (+\u002F- 15%) and BMI (+\u002F- 3 kg\u002Fm2).\n\nExclusion Criteria\n\n* Lack of mental capacity to give informed consent\n* Age \\\u003C6 years; \\>99 years\n\nAdditional exclusions for MRI assessments:\n\n* Cochlear Implant\n* Aneurysm Clips\n* Neurological stimulator\n* Implanted cardiac devices (ICD, PPM, loop recorders, or any others)\n* Metal heart valve\n* History of metal foreign bodies in orbits\n* Other implanted metal device which prevents MRI\n* Known claustrophobia.","6 Years","99 Years",{"count":118,"type":20},50,"This observational 'recruit by genotype' study aims to provide insights into the cellular and molecular pathways underlying beta cell disorders and their physiological consequences. Eligible individuals are those with and without a pathogenic genetic variant, acting as case and control, respectively. Using a \"recruit by genotype\" approach, the researchers will perform detailed and specific analysis according to the individual's genetic variant.\n\nThe study's main aims are to : 1) identify and describe biomarkers and cellular features in blood samples that occur because of the rare causal genetic variant; 2) study the altered physiology or cellular function that are due to the rare causal genetic variant.\n\nParticipants will attend a study visit that will entail:\n\n* Consent\n* Data collection\n* Height and weight measures\n* Blood samples\n* MRI (optional), dependent on genotype and sub-study objectives.\n\nThere is no treatment and the participants' normal clinical care will be unaffected and will continue uninterrupted.\n\nA small subset of participants may be invited for further sub-studies in the future. Researchers may recruit sex-matched healthy controls (without the variant of interest) with similar age and BMI (age: +\u002F-15%, BMI: +\u002F- 3 kg\u002Fm2) for specified case-control studies.",[121,122,27],"Diabetes Mellitus","Monogenic Diabetes",[122,27,124,125,126,127],"Beta cell disorders","Genotype-to-phenotype","Causal genetic variant","Beta cell","2026-01-14",{"date":130,"type":33},"2026-01-16",{"date":132,"type":33},"2025-11-11",{"date":134,"type":20},"2029-02-28",{"name":136,"class":40},"University of Exeter",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":41},"100446081","phase-2-utility-of-18fdopa-petmri-for-focal-hyperinsulinism-100446081","NCT05088798","Utility of 18FDOPA PET\u002FMRI for Focal Hyperinsulinism","Use of18F-DOPA PET\u002FMRI for the Detection and Localization of Focal Forms of Hyperinsulinism","18FDOPA HI","Inclusion Criteria:\n\n1. Patients with confirmed hyperinsulinemic hypoglycemia, diagnosed by elevated insulin levels during hypoglycemia and\u002For response to glucagon stimulation.\n2. Subjects who failed pharmacological therapy with diazoxide or octreotide.\n3. Subjects with signed informed consent by themselves or their parents or legal guardians.\n4. Patient's Endocrinologist has determined that the patient cannot be safely managed with standard medical therapy (failed) and surgery is recommended to prevent future episodes of severe hypoglycemia and preserve brain function.\n\nExclusion Criteria:\n\n1. Any other major illness or condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in this study.\n2. Patient must not have any contraindication to MRI as evaluated by a standardized MRI safety questionnaire. If MRI is contraindicated, and patient meets inclusion criteria and has no other contraindications study will be conducted in PET\u002FCT scanner.\n3. Cases in which surgery will not be considered by parents or guardians.",{"count":146,"type":20},100,[148],"PHASE2","The purpose of the study is to provide access to 18F-DOPA PET to patients at Washington University and assess the utility of 18F-DOPA PET\u002FMRI as a preoperative tool to detect and localize focal lesions in the pancreas that are causing hyperinsulinism.",[27],[152,93,153,27,154],"hypoglycemia","Infant, Newborn, Diseases","Insulinoma","2025-12-17",{"date":157,"type":33},"2025-12-19",{"date":159,"type":33},"2020-09-10",{"date":161,"type":20},"2030-01-01",{"name":163,"class":40},"Washington University School of Medicine",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":41},"100584447","cardiovascular-and-endothelial-markers-during-ogtt-before-and-at-six-and-twelve-months-post-treatment-in-women-with-pcos-100584447","NCT06889454","Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS","The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome","Inclusion Criteria:\n\n1. Age \\> 16 years old\n2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:\n\n   * Clinical or biochemical hyperandrogenism\n   * Anovulation or oligo-ovulation\n   * Polycystic ovarian morphology (PCOM)\n3. Absence of treatment for PCOS the last six months\n4. Patients who have the ability to understand and sign the consent form.\n\nExclusion Criteria:\n\n1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \\[17-OHP\\]), Cushing syndrome, acromegaly\n2. Treatment with contraceptive or metformin\n3. Type 2 diabetes mellitus\n4. Treatment for diabetes\n5. Pregnancy\n6. Lactation\n7. Malignancy","45 Years",{"count":173,"type":20},120,"The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.",[63,27,176,61],"Hyperandrogenism","2025-11-15",{"date":179,"type":33},"2025-11-19",{"date":70,"type":33},{"date":182,"type":20},"2026-02-01",{"name":184,"class":40},"Attikon Hospital",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":41},"100490135","assessment-of-pancreatic-beta-cell-mass-and-function-by-positron-emission-tomography-imaging-in-human-diabetes-mellitus-100490135","NCT05662189","Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus","Assessment of Pancreatic Beta Cell Mass and Function with the Aid of Positron Emission Tomography Imaging in Human Diabetes Mellitus","Inclusion Criteria:\n\n* Age ≥18 years; ≤ 75 years\n* Both sexes\n* Good health\n* Absence of exclusion criteria\n* Able to understand methods, goals, and implications of the research and of delivering a free, written informed consent\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C 12 g\u002Fdl\n* HbA1c \\> 10%\n* Pregnancy or breast-feeding\n* If not in menopause, women not using effective birth control methods or not willing to undergo a pregnancy test\n* History of severe psychiatric disorder or alcohol abuse\n* Recent head traumas (\\\u003C6 months)\n* Active neurologic diseases\n* Claustrophobia\n* Active malignant neoplasms\n* Severe kidney and\u002For liver disease\n* Recent (\\\u003C6 months) major adverse cardiovascular events\n* Heart failure (class NYHA 3-4)\n* Drugs known to affect beta cell function and\u002For insulin sensitivity\n* Current or past treatment with GLP1R-agonists\n* Intolerance to exenatide\n* Endocrine diseases, other than diabetes mellitus, known to affect beta cell function and\u002For insulin sensitivity, except well controlled hypothyroidism or adrenal insufficiency\n* COPD on day time oxygen therapy\n* Any current acute disease","75 Years",{"count":194,"type":20},70,[86],"The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.",[198,199,200,27],"Type1diabetes","Type2diabetes","Pre Diabetes",[202,203,204,205],"diabetes","beta-cell","exendin","PET-CT","2025-03-14",{"date":208,"type":33},"2025-03-18",{"date":210,"type":33},"2022-03-15",{"date":212,"type":20},"2025-12",{"name":214,"class":40},"Azienda Ospedaliero-Universitaria di Parma",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":41},"100497162","early-phase-1-a-pilot-study-of-monitoring-insulin-levels-and-treating-hyperinsulinemia-and-hyperglycemia-with-pioglitazone-in-patients-treated-with-alpelisib-for-metastatic-breast-cancer-100497162","NCT05753657","A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.","Inclusion Criteria:\n\n* Patients with ER positive HER2 negative metastatic breast cancer, harboring an activating PIK3CA mutation, scheduled to start treatment with Alpelisib and fulvestrant.\n* Ages 18 - 85\n* ECOG performance status 0, 1 or 2\n* Ability to understand and willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Alpelisib\n* Uncontrolled diabetes mellitus, defined as HbA1c above 8%\n* Diabetes mellitus controlled by insulin\n* Uncontrolled intercurrent illness including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnancy\n* Known allergy to pioglitazone","85 Years",{"count":223,"type":20},30,[225],"EARLY_PHASE1","The goal of this study is to test whether monitoring insulin levels and using pioglitazone to treat hyperglycemia and hyperinsulinemia in patients treated with Alpelisib for metastatic breast cancer is feasible and safe, and to assess the rates of glycemic control, dose reductions and treatment discontinuation and the progression free survival of patients treated with this regimen.",[228,27,229],"Metastatic Breast Cancer","Hyperglycemia Drug Induced","2023-02-22",{"date":232,"type":33},"2023-03-03",{"date":234,"type":33},"2022-12-25",{"date":236,"type":20},"2027-12-31",{"name":238,"class":40},"Rambam Health Care Campus"]